AxoGen, Inc. reports results for the quarter ended September 30 - Earnings Summary

• AxoGen, Inc. reported quarterly adjusted earnings of 21 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 12 cents. The mean expectation of eleven analysts for the quarter was for earnings of 14 cents per share. Wall Street expected results to range from 12 cents to 16 cents per share.

• Revenue rose 26.2% to $75.83 million from a year ago; analysts expected $73.20 million.

• AxoGen, Inc.'s reported EPS for the quarter was 4 cents​.

• The company reported quarterly net income of $2.33 million.

• AxoGen, Inc. shares had fallen by 10.6% this quarter and gained 14.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for AxoGen, Inc. is $53.00, about 29.3% above its last closing price of $37.46

This summary was machine generated from LSEG data October 28 at 02:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)